Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin3-yl)-isoindole-1-3-dione

Details for Australian Patent Application No. 2006208201 (hide)

Owner Celgene Corporation

Inventors Muller, George W.; Chen, Roger S.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2006208201

PCT Pub. Number WO2006/081251

Priority 60/646,505 25.01.05 US

Filing date 24 January 2006

Wipo publication date 3 August 2006

International Classifications

A61K 31/454 (2006.01)

A61P 19/02 (2006.01) Drugs for skeletal disorders

A61P 35/00 (2006.01) Antineoplastic agents

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

23 August 2007 PCT application entered the National Phase

  PCT publication WO2006/081251 Priority application(s): WO2006/081251

14 January 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006208208-GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis

2006208199-Conjugates of biologically active proteins having a modified in vivo half-life